Quarterly Report Q3 2026: Orviglance(R) Update Following FDA Type A ...
(PR-inside.com) MALMÖ, SE / ACCESS Newswire / November 5, 2026 / Ascelia Pharma AB (publ)(STO:ACE) today published its Interim Report Q3 for 2026 (January - September), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q3 2026 Publication of Orviglance clinical study in Journal …
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


